Quizartinib for Newly Diagnosed FLT3-ITD–Negative AML

27 Mar 20264 min read0 viewsJournal Feed

GIST

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 27 Mar 2026. The item focuses on Quizartinib for Newly Diagnosed FLT3-ITD–Negative AML. Review the original article for the full source wording and details.

Clinical Editorial

Summary

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 27 Mar 2026.

The item focuses on Quizartinib for Newly Diagnosed FLT3-ITD–Negative AML.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Br J CancerRelated by Conditionleukemia

SLIRP Maintains Mitochondrial mRNA Stability and OXPHOS in Colorectal Cancer

Oncology • 28 Apr 2026

ClinicalTrialsRelated by Conditionleukemia

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Oncology • 06 Apr 2026

ClinicalTrialsRelated by Conditionleukemia

A Phase 1/2 Study of LBS-007 in Relapsed or Resistant Acute Leukaemias

Oncology • 27 Mar 2026

Nat Rev OncRelated by Conditionleukemia

A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions

Oncology • 14 Apr 2026

Nat Rev OncRelated by Conditionleukemia

A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions

Oncology • 14 Apr 2026

Br J CancerRelated by Conditionleukemia

Apoptotic Modulators Enhance Oncolytic Virus-Induced Cytokine Killing in Acute Myeloid Leukemia

Oncology • 10 Apr 2026

Feed Metadata

Source

Journal of Clinical Oncology (JCO)